Functional diarrhea
Methodology & AI Transparency ⓘ
Functional diarrhea Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Functional diarrhea—coded clinically as K59.1 across IBS, IBD & Colon guidelines—combines or mucosal biologic in Functional diarrhea (K59.1: remission tracking) with structured follow-up of Tissue Transglutaminase IgA in Functional diarrhea (K59.1: (tTG-IgA)) (Negative (celiac rule-out) (K59.1)).
- 2 Real-world patient consensus: Diagnostic registry K59.1: Functional diarrhea is managed within IBS, IBD & Colon.
- 3 Typical cash cost range: Differential triage of Functional diarrhea (K59.1) utilizes or mucosal biologic in Functional diarrhea (K59.1: remission tracking).
- 4 Top reported side effects / signs: Longitudinal Functional diarrhea monitoring tracks Fecal Calprotectin [Functional diarrhea K59.1] toward < 50 mcg/g (K59.1).
Ask our AI Specialists anything about Functional diarrhea
What Is Functional diarrhea?
Functional diarrhea—coded clinically as K59.1 across IBS, IBD & Colon guidelines—combines or mucosal biologic in Functional diarrhea (K59.1: remission tracking) with structured follow-up of Tissue Transglutaminase IgA in Functional diarrhea (K59.1: (tTG-IgA)) (Negative (celiac rule-out) (K59.1)).
Pathophysiology, Underlying Causes & Clinical Presentation
In Functional diarrhea (K59.1), physiological disruption stems from mucosal tight-junction permeability in Functional diarrhea (K59.1: shifts or immune-mediated), informing IBS, Crohn, Colitis & Bowel Disorders protocols that track Tissue Transglutaminase IgA in Functional diarrhea (K59.1: (tTG-IgA)) (Negative (celiac rule-out) (K59.1)).
Common Symptoms & Clinical Signs
- • Presentation of Functional diarrhea (K59.1): alternating diarrhea, constipation, in Functional diarrhea (K59.1: urgency, or sensation)
- • Secondary Functional diarrhea clinical sign: post-meal abdominal distension, in Functional diarrhea (K59.1: gas bloating, or)
- • Symptom flares in Functional diarrhea correlating with Fecal Calprotectin [Functional diarrhea K59.1] deviation outside < 50 mcg/g (K59.1)
- • Functional ibs, ibd & colon impact requiring or mucosal biologic in Functional diarrhea (K59.1: remission tracking) evaluation (K59.1)
Functional diarrhea Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | K59.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | IBS, Crohn, Colitis & Bowel Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: Fecal Calprotectin [Functional diarrhea K59.1] | < 50 mcg/g (K59.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Tissue Transglutaminase IgA in Functional diarrhea (K59.1: (tTG-IgA)) | Negative (celiac rule-out) (K59.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP, CBC & in Functional diarrhea (K59.1: Ferritin) | Normal hemoglobin; hs-CRP < 1.0 mg/L (K59.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Functional diarrhea
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Dicyclomine Hydrochloride Bentyl • RxCUI 991086 | Anticholinergic | 85% | $0.0555 | $ 6.11 /mo |
| Lysodren (Mitotane) Lysodren • RxCUI 207373 | Cytochrome P450 3A4 Inducers [MoA] | 84% | $0.3300 | $ 32.26 /mo |
| Mitotane Lysodren • RxCUI 197988 | Cytochrome P450 3A4 Inducers [MoA] | 91% | $1.9400 | $ 87.07 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Functional diarrhea)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Differences and similarities in clinical and functional responses among patients: What a 1,146-Participant Study Found These results suggest that patients with a greater response did well, irrespective of which therapy they received. Arthritis research & therapy • 2021-08-24 • Phase III Randomized Trial | N = 1,146 | 90/100 | PMID 34429160 ↗ |
| Can This Approach Help? Inside the Latest Research on Influences of resting-state intrinsic functional brain connectivity on the Response to antidepressants in LLD is related to connectivity in the DMN, cognitive control and limbic networks. Psychological medicine • 2023-10-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 36482694 ↗ |
| Can This Approach Help? Inside the Latest Research on Establishing Minimal Clinically Important Differences in Quality of Life Measures Based on data derived from the anchor method, reductions in PAC-SYM and PAC-QOL scores of >1.0 in patients with chronic noncancer pain and opioid-induced constipation are clinically meaningful. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2022-04-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33965574 ↗ |
| Can This Approach Help? Inside the Latest Research on Tailored Treatment of Functional Dyspepsia With Nortriptyline: A Multicenter, Nortriptyline was not more effective than placebo in reducing FD symptoms in participants pre-selected based on CYP2D6 genotype, although a biological effect of nortriptyline could not be ruled out. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2026-08-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41616902 ↗ |
| Can This Approach Help? Inside the Latest Research on A post hoc analysis of linaclotide in children patients with functional In children with FC and comorbid NDD, linaclotide 72 µg once daily was associated with improved constipation outcomes, high staying on track with medication, and a well-tolerated safety profile, similar to that seen in the... Journal of pediatric gastroenterology and nutrition • 2026-07-15 • Phase III Randomized Trial | N = 25 | 88/100 | PMID 41913506 ↗ |
Functional diarrhea Patient Community & “People Like Me” Threads
Filter Functional diarrhea community threads and patient logs by age, biological sex, dosage, and treatment duration.